Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Axin

Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101525

Synonyms

Historical Background

A fundamental process in embryonic development is the establishment of body axes, including the anteroposterior (A-P) axis, the dorsoventral (D-V) axis, and the left-right (L-R) axis. Back to 1940s, when signaling pathways and molecular mechanisms behind axis formation remained a mystery, a spontaneous mutation called Kinky (Fu Ki ) at the mouse Fused locus attracted attention due to its impact on a variety of developmental processes, especially on the formation of embryonic A-P axis(Gluecksohn-Schoenheimer 1949). Around 1990s, two other spontaneous alleles of the mouse Fused gene, Fused (Fu Fu ) and Knobbly (Fu Kb ), and one transgenic insertional mutant Fu Tg1 were identified (Jacobs-Cohen et al. 1984; Perry et al. 1995; Mary et al. 1996), all showing defects in the formation of embryonic axis. These Axin null mutants normally led to lethality at embryonic day 8–10, and in addition to causing embryonic axis duplications, they also led to neuroectodermal and cardiac abnormalities (Jacobs-Cohen et al. 1984; Perry et al. 1995; Mary et al. 1996). Meanwhile, during 1990s, the requirement of Wnt signaling pathway for the development of embryonic axes became increasingly clear and several studies confirmed the essential role of β-catenin, the central player of canonical Wnt signaling, in the establishment of embryonic axes (Heasman et al. 1994; Fagotto et al. 1996; Miller and Moon 1996). In 1997, Zeng and colleagues revealed involvement of the Fused gene in the Wnt signaling pathway and showed that the Fused gene affects the formation of embryonic axis through a negative regulation of the Wnt pathway (Zeng et al. 1997). They renamed the Fused gene as Axin for ax is in inhibition to distinguish it from another unrelated Drosophila gene fuse (Zeng et al. 1997). Soon after that, a number of studies confirmed Axin as an essential component of Wnt pathway and these studies also uncovered Axin as a key scaffold protein in a complex for directing β-catenin degradation (Behrens et al. 1998; Hart et al. 1998; Ikeda et al. 1998; Itoh et al. 1998; Kishida et al. 1998; Nakamura et al. 1998; Sakanaka et al. 1998). In 1998, two independent studies identified a homolog of Axin, designated as Conduction and Axil respectively (Behrens et al. 1998; Yamamoto et al. 1998). Soon, it was confirmed that Conductin and Axil are the same protein with similar function to that of Axin by negatively regulating Wnt pathway (Kikuchi 1999; Mai et al. 1999). To differentiate these two Axins, Axin is thereafter also known as Axin1, with Conductin/Axil as Axin2.

Structure of Axin

Human Axin (hAxin) has two isoforms, isoform-a and isoform-b, which contains 862 and 826 amino acids respectively. There are several other forms of hAxin used especially in the early literature such as the one containing 900, 956, or 996 amino acids (Kusano and Raab-Traub 2002; Smalley et al. 1999; Mao et al. 2001). These different versions of Axin normally contain extra ~40–130 amino acids at the N-terminus which may not be present in the functional endogenous Axin protein. So far, the most-used Axin in the literature is a short form of mouse Axin which contains 832 amino acids. Hence, the amino acid numbers of Axin indicated in the text below refer to this mouse Axin of 832 amino acids. Axin contains a RGS (aa 89–216) and a DIX domain (aa 756–832) at its N- and C-terminus respectively (Fig. 1). The RGS domain shares amino acid sequence homology with the RGS family proteins and is sufficient for an interaction with APC (tumor suppressor adenomatous polyposis coli) – another key component of the complex for driving β-catenin degradation. Previously it is considered that the RGS domain of Axin was unable to interact with Gα proteins as do its homologous RGS proteins. However, it was later uncovered that the RGS domain of Axin specially binds to Gαs in an aluminum-dependent manner (Castellone et al. 2005). In 2000, the crystal structures of the Axin RGS domain alone and in complex with an Axin-binding fragment of APC were determined (Spink et al. 2000). The RGS domain of Axin exists as a monomer, while the C-terminal DIX domain forms oligomers (Fig. 1). Besides Axin, the homologous DIX domain is also present in other two proteins, Dvl and Ccd1 (also called DIXdc1). The three-dimensional structures of these DIX domains showed that DIX forms a filament-like assembly through head-to-tail self-interaction (Schwarz-Romond et al. 2007; Shibata et al. 2007). The DIX domain is believed to function though mediating homo- and hetero-interactions (Li et al. 1999; Schwarz-Romond et al. 2007; Choi et al. 2010; Fiedler et al. 2011). Between the RGS and DIX domain is the central region comprising ~600 amino acids, which is responsible for the interactions of Axin with most of its partners. Of note, this central region could be largely disordered and may adopt secondary structures or change conformations upon binding with partners (Noutsou et al. 2011).
Axin, Fig. 1

Structure of Axin. (a) Schematic representation of domain organization of Axin. It contains two domains, the N-terminal RGS and the C-terminal DIX domain. The central region is largely predicted as unfolded structures, which may adopt secondary structures upon binding partners. (b and c) The crystal structures of RGS domain (PDB code: 1dk8) and DIX domain (PDB code: 1WSP). The RGS domain exists as a monomer in the crystal structure, while the DIX domain self-interacts and forms filament-like oligomer in the crystal

Axin in Canonical Wnt Signaling

Dual Roles of Axin in Transmitting Canonical Wnt Signals

The Wnt signaling pathway is highly conserved in organisms ranging from nematode worms to mammals, and it controls many fundamental physiological processes such as cell growth, tissue morphogenesis, and embryonic development (MacDonald et al. 2009). The signal transduction is launched by binding of a group of Wnt proteins to their membrane receptors, and according to whether β-catenin is essential for the signal transduction, the Wnt signaling pathway has been so far classified into two classes: canonical Wnt pathway (also known as Wnt/β-catenin pathway) and noncanonical Wnt pathway (including planar cell polarity pathway and Wnt/calcium pathway). In Wnt/β-catenin pathway (hereinafter referred to as Wnt pathway), when there is no Wnt stimulation, the central player β-catenin is sequestered in a complex called “β-catenin destruction complex” (hereinafter referred to as destruction complex), in which β-catenin is subjected to GSK3β/CK1-mediated phoshorylation followed by TRCP (transducin repeat containing E3 ubiquitin protein ligase)-mediated ubiquitination and subsequent proteasome-dependent degradation. When Wnt ligands bind to the membrane receptors consisted of frizzled and LRP5/6 (LDL receptor related protein 5/6), the destruction complex is functionally inhibited, which allows β-catenin to escape degradation and subsequently enter the nucleus where it forms a transcriptional complex with LEF1/TCF4 to induce target gene expression. Axin interacts directly with multiple key components in the destruction complex such as β-catenin, APC, and GSK3β (glycogen synthase kinase 3β), by which Axin brings these proteins together to efficiently regulate the activity of β-catenin.

In addition to mediating assembly of the destruction complex, in 2001, Mao and colleagues reported a new role of Axin in Wnt signaling (Mao et al. 2001). They found that Wnt stimulation induced a translocation of Axin to the membrane to interact with LRP5/6, and this interaction between Axin and LRP5/6 is essential for Wnt signal transduction (Mao et al. 2001). Later studies confirmed that upon Wnt stimulation, Axin moves to interact with LRP5/6, which brings GSK3β/CKI (casein kinase I) to the membrane receptor for phosphorylation of LRP5/6; while phosphorylated LRP5/6 has an increased affinity for Axin, which, in turn, promotes recruitment of more Axin protein to LRP5/6 (Davidson et al. 2005; Zeng et al. 2005; Bilic et al. 2007). These studies established the second role of Axin in Wnt signaling by prompting LRP5/6 phosphorylation upon Wnt stimulation. As such, Axin plays dual roles in the Wnt/β-catenin signaling: on one hand, it mediates formation of the destruction complex to prompt β-catenin degradation in the absence of Wnt signals, thereby inhibiting Wnt signal transduction; on the other hand, it brings GSK3β/CK1 close to the membrane receptor to phosphorylate LRP5/6 upon Wnt stimulation, thereby facilitating Wnt signal transduction (Fig. 2). In addition to the partners mentioned above, Axin exhibits incredible scaffolding ability by binding with amazingly various proteins. So far, ~70 proteins have been added to the Axin-interacting protein list and this list continues to grow. These Axin-interacting proteins participate into the β-catenin destruction complex or other signaling complexes through a physical interaction with Axin, by which they either positively or negatively regulate Wnt signaling or other signaling pathways to affect a wide range of cell behaviors.
Axin, Fig. 2

Dual role of Axin in the canonical Wnt signaling. At the Wnt-off state, Axin scaffolds the destruction complex through complexing with APC, β-catenin, GSK3β, and CKI to facilitate β-catenin degradation; upon Wnt stimulation, Axin translocates to interact with membrane receptor LRP5/6 and brings GSK3β/CKI close to LRP5/6, thereby facilitating LRP5/6 phosphorylation and consequently activation of Wnt signaling. Of note, both the destruction complex and the LRP5/6 signaling complex contain many other proteins in addition to the ones illustrated. For brevity and clarity, only several major components are displayed in the illustration

Posttranslational Modifications of Axin

As the concentration-limiting component of the destruction complex, the function of Axin is subject to multiple posttranslational modifications including phosphorylation, ubiquitination, methylation, and sumolyation (Song et al. 2014). Generally, phosphorylated Axin catalyzed by GSK3β shows enhanced stability and increased affinities with its binding partners, while dephoshorylation has the reverse effect on Axin stability and function (Jho et al. 1999; Willert et al. 1999; Yamamoto et al. 1999; Strovel et al. 2000). In addition to GSK3β, CKI was also observed to phosphorylate Axin both in vitro and in vivo (Gao et al. 2002). Another study suggested that phosphorylation of Axin by CKI may promote Axin-GSK3β interaction, leading to a more active destruction complex; while protein phosphatase 1 (PP1) dephosphorylates Axin and reverses the effect conferred by CKI (Luo et al. 2007). Moreover, phosphorylation of Axin by Cyclin A/CDK2 was reported to increase its association with β-catenin (Kim et al. 2004). Recently, Axin was found to be also phosphorylated by CDK5, and this phosphorylation facilitates its interaction with GSK3β, which plays an essential role for axon development (Fang et al. 2011). On the other hand, PP2A and PP2C are the other two phosphatases that may mediate dephosphorylation of Axin, thereby suppressing the function of Axin and facilitating disassembly of the destruction complex (Willert et al. 1999; Strovel et al. 2000). A recent study by Kim and colleagues provides some insights into the mechanisms behind how phosphorylation/dephosphorylation may affect the interaction of Axin with its partners (Kim et al. 2013). Their studies indicate that phosphorylation of Axin may release an auto-inhibited conformation of Axin, and the Axin protein in this “open” state may have increased affinities with its binding partners, such as β-catenin and LRP5/6 (Kim et al. 2013).

In 2009, Stegmeier and colleagues revealed that poly-ADP-ribose modification (PARsylation) of Axin by Tankyrase (TNKS) plays a critical role in regulating Axin stability and function (Huang et al. 2009). Further studies indicated that PARsylated Axin is probably recognized by the E3 ligase RNF146 for ubiquitination and subsequent proteasomal degradation (Huang et al. 2009; Callow et al. 2011; Zhang et al. 2011). On the other hand, ubiquitin-specific protease 34 (USP34) is reported to counteract this TNKS-RNF146-meidated reaction on Axin, thereby promoting nuclear accumulation of Axin to positively influence β-catenin-mediated transcription (Lui et al. 2011). Ubiquitin ligase Smurf1 and its homologs protein Smurf2 are E3 ligases which both targets Axin for ubiquitination. However these two Smurfs exert distinct effects on Axin function: Smurf2-mediated ubiquitination causes Axin degradation and thus prompts Wnt signal transduction, while Smurf1-mediated ubiquitination of Axin disrupts the interaction of Axin with LRP5/6 rather than leads to its degradation, thereby downregulating Wnt signaling (Kim and Jho 2010; Fei et al. 2013). In addition to ubiquitination, sumoylation is also reported to play a role in regulating Axin function. An early study in 2002 showed that sumoylation at the extreme C-terminal six amino acids of Axin is required for Axin-mediated JNK activation but dispensable for Wnt signaling (Rui et al. 2002). Later, Kim and colleagues suggested that this sumoylation at the C-terminus protects Axin from ubiquitination and thus enhances its stability (Kim et al. 2008). In 2011, Cha and colleagues reported methylation of Axin catalyzed by PRMT1, which leads to enhanced Axin stability and increased Axin-GSK3β interaction (Cha et al. 2011).

Axin Functions beyond Wnt Signaling

Soon after the discovery of Axin as a critical player in Wnt signaling, Zhang and colleagues reported the involvement of Axin in JNK pathway through forming a complex with MEKK1 (Zhang et al. 1999). After that, it is increasingly recognized that the role of Axin as a scaffold protein extends far beyond the one in the Wnt signaling. Axin, through interacting with distinct sets of proteins, mediates the assembly of multiple signaling complexes, by which Axin exerts important effects on signaling pathways including TGF-β, JNK, P53 as well as other pathways (Fig. 3).
Axin, Fig. 3

In addition to Wnt signaling, Axin also participates into the regulation of p53, JNK, TGF-β as well as other pathways. In p53 signaling, Axin bridges both positive and negative regulators to the P53 complex to facilitate HIPK2-mediated phosphorylation and activation of p53. In JNK signaling, Axin interacts directly with MEKKs and other proteins, thereby regulating JNK activation. In TGF-β signaling, Axin interacts directly with Smads and other proteins, thereby positively affecting TGF-β signal transduction. Of note, only several major components are displayed for each signaling complex in the illustration

In TGF-β signaling, Axin interacts directly with Smad2/3, facilitating Smad2/3 activation and thus TGF-β signal transduction (Furuhashi et al. 2001). In addition to reinforcing the function of the positive regulators of TGF-β signaling like Smad2/3, Axin is also found to facilitate TGF-β signal transduction through suppressing the function of the negative regulator Smad7. Axin brings Smad7 and the ubiquitin E3 ligase Arkadia together, thereby promoting Arkadia-mediated degradation of Smad7 and prompting TGF-β signaling (Liu et al. 2006). Axin is also involved in the regulation of the basal activity of Smad3 through facilitating GSK3β-mediated Smad3 phosphorylation and its subsequent degradation in the absence of TGF-β signals (Guo et al. 2008).

Axin interacts with a couple of important components in JNK pathway. Axin utilizes distinct regions to interact with MEKK1 and MEKK4 and this may confer Axin the ability to regulate JNK activation according to distinct signals or in different cellular contexts (Zhang et al. 1999; Luo et al. 2003). On the other hand, the interaction between Axin and the I-mfa domain proteins HIC and I-mfa blocks Axin-MEKK interaction, thus decreasing Axin-mediated JNK activation (Kusano and Raab-Traub 2002). The interaction of HIC and I-mfa with Axin may also affect the activity of Axin in Wnt signaling, through affecting the formation of Axin-GSK3β-catenin complex (Kusano and Raab-Traub 2002). As mentioned before, Axin is heavily sumoylated at its extreme C-terminal six amino acids. Axin binds to the SUMO-1-conjugating enzyme E3 PIAS (protein inhibitor of activated STAT) including PIAS1, PIASxβ, and PIASy through its C-terminal region. Sumoylation of Axin by these PIAS family proteins is essential for Axin to promote JNK activation (Rui et al. 2002).

Axin interacts directly with p53. In addition, Axin bridges both positive and negative regulators to the p53 complex to regulate p53 activation. Knockdown of Axin by siRNA leads to impaired activation of p53, highlighting the functional significance of Axin in p53 pathway (Rui et al. 2004; Li et al. 2007). Axin directly interacts with HIPK2, a key kinase in activating p53, which brings HIPK2 close to the Axin-bound p53 protein to facilitated HIPK2-mediated p53 phosphorylation and activation. Meanwhile, Axin-HIPK2 interaction may induce a conformational change of HIPK2, increasing HIPK2 activity to phosphorylate and activate p53 (Rui et al. 2004). In addition to p53 and HIPK2, Axin is reported to bind directly to other regulators including PML (Promyelocytic leukemia protein), Tip60, Pirh2, (Li et al. 2007, 2009, 2011) and Daxx (Death domain-associated protein 6). As a key scaffold protein, Axin brings these proteins close to form a functional complex, in which these proteins cooperate with each other to keep p53 activity under tight control.

In addition to the above signaling pathways, Axin is also involved in regulating other pathways. For example, Axin directly interacts with LKB1 and AMPK holoenzyme, facilitating LKB1-mediated phosphorylation of AMPK and AMPK activation (Zhang et al. 2013). Axin also joins up GSK3β, Pin, and PP2A-B56 to form a degradation for c-Myc, facilitating proteasomal degradation of c-Myc and suppressing cell proliferation. Of note, the studies of Axin in different pathways consistently relate Axin to a function of promoting apoptosis, suggesting that Axin may serve as a general regulator to suppress cellular proliferation.

Axin as a Drug Target

Considering the significant role of Wnt signaling in many aspects of controlling cell behaviors, it is not surprising that dysregulation of Wnt signaling would lead to tumors as well as other diseases like bone disease and metabolic disease (Clevers and Nusse 2012). So far, mutation or aberrant expression of components of Wnt signaling has been closely related to the generation and progression of a number of human cancers (Polakis 2012). A striking example is in colorectal cancer, in which alterations of APC have been observed in ~90% of tumor samples (Miyaki et al. 1994; Najdi et al. 2011). Around 2000, several mutations in Axin1 and Axin2 were firstly identified in hepatocellular carcinoma (HCC) and hepatoblastoma (HB) (Taniguchi et al. 2002). Soon thereafter, impaired activation of Axin was implicated in a variety of other human cancers such as lung cancer (Hughes and Brady 2006; Kanzaki et al. 2006), breast cancer (Ozaki et al. 2005), colon cancer (Lammi et al. 2004; Parveen et al. 2011; Yang et al. 2013), and prostate cancer (Yardy et al. 2009). Despite these findings, the role of Axin as a drug target has not been realized until the discovery of Tankyrases (TNKS) inhibitors. In a large-scale screening to find drug leads against Wnt signaling, a small-molecule inhibitor IWR-1 was identified (Chen et al. 2009). Later, another inhibitor XAV939 was identified and it was then revealed that both IWR-1 and XAV939 target TNKS and inhibit the enzyme activity of TNKS (Huang et al. 2009). As mentioned above, TNKS mediates PARsylation of Axin, leading to ubiquitination and degradation of Axin (Huang et al. 2009). Thus inhibition of TNKS could improve Axin stability and promote Axin-mediated degradation of β-catenin. Since identification of the initial TNKS inhibitors of IWR-1 and XAV939, a couple of new TNKS inhibitors have been identified including WIKI4, JW55, G007-LK, and G244-LM, and they all show promising antitumor activity through stabilizing Axin (Huang et al. 2009; James et al. 2012; Waaler et al. 2012; Lau et al. 2013). In 2012, the 3D structure of TNKS in complex with Axin was determined (Morrone et al. 2012). This structure is expected to facilitate the development of more specific modulators that target the TNKS-Axin interface. In addition to TNKS inhibitors, two other small-molecule compounds, SKL2001 and HLY78, have been identified through high-throughput screening with Axin as their cellular target. However, unlike TNKS inhibitors, these two compounds promote activation of Wnt signaling instead of blocking it, although they do it through different mechanisms (Gwak et al. 2012; Wang et al. 2013). SKL2001 disrupts the interaction between Axin and β-catenin, thus increasing the stability of β-catenin; while HLY78 induces a conformational change of Axin, leading to an enhanced Axin-LRP5/6 interaction. SKL2001 and HLY78 show promising activities in the aspects like stem cell renewal and bone fracture repair, in which enhancement of Wnt signaling is preferred.

Summary

Axin was initially established as a negative regulator of Wnt signaling. In the Wnt-off state, Axin interacts with multiple key components in the destruction complex to facilitate the degradation of β-catenin; whereas in the Wnt-on state, Axin moves to interact with the membrane receptor LRP5/6, by which Axin brings GSK3β/CK1 close to LRP5/6, leading to LRP5/6 phosphorylation and thus promoting Wnt signal transduction. Axin is well known as a key component of Wnt signaling, however its master scaffolding function is hardly limited to the Wnt signaling. Current findings have related Axin to several other signaling pathways such as JNK, P53, and TGF-β. With the discoveries of new binding partners of Axin, more functions of Axin are expected to be uncovered in the future. Based on the current knowledge, Axin may serve as a connecting point among different signaling pathways for a negative regulation of cell growth. Aberrant activation of Axin has so far been implicated in various human cancers especially in hepatocellular and colorectal cancer. The discovery of TNKS inhibitors which show potent antitumor activities by increasing Axin stability further points out Axin as a promising druggable target for cancer treatment. Axin has no enzymatic activity itself and it functions through interacting with different sets of binding partners to affect various signaling pathways that are closely related to pathogenesis of human disease. Hence modulators targeting those Axin-mediated protein-protein interactions (PPIs) may have potentials as drug target for treating human disease. However, before that, more studies and clinical data are required to classify the specific roles of those Axin-mediated PPIs in human disease.

References

  1. Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R, et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science. 1998;280:596–9.CrossRefPubMedGoogle Scholar
  2. Bilic J, Huang YL, Davidson G, Zimmermann T, Cruciat CM, Bienz M, et al. Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science. 2007;316:1619–22. doi: 10.1126/science.1137065.CrossRefPubMedGoogle Scholar
  3. Callow MG, Tran H, Phu L, Lau T, Lee J, Sandoval WN, et al. Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling. PLoS One. 2011;6:e22595. doi: 10.1371/journal.pone.0022595.PubMedCentralCrossRefPubMedGoogle Scholar
  4. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science. 2005;310:1504–10. doi: 10.1126/science.1116221.CrossRefPubMedGoogle Scholar
  5. Cha B, Kim W, Kim YK, Hwang BN, Park SY, Yoon JW, et al. Methylation by protein arginine methyltransferase 1 increases stability of Axin, a negative regulator of Wnt signaling. Oncogene. 2011;30:2379–89. doi: 10.1038/onc.2010.610.CrossRefPubMedGoogle Scholar
  6. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol. 2009;5:100–7. doi: 10.1038/nchembio.137.PubMedCentralCrossRefPubMedGoogle Scholar
  7. Choi SH, Choi KM, Ahn HJ. Coexpression and protein-protein complexing of DIX domains of human Dvl1 and Axin1 protein. BMB Rep. 2010;43:609–13. doi: 10.5483/BMBRep.2010.43.9.609.CrossRefPubMedGoogle Scholar
  8. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012;149:1192–205. doi: 10.1016/j.cell.2012.05.012.CrossRefPubMedGoogle Scholar
  9. Davidson G, Wu W, Shen J, Bilic J, Fenger U, Stannek P, et al. Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. Nature. 2005;438:867–72. doi: 10.1038/nature04170.CrossRefPubMedGoogle Scholar
  10. Fagotto F, Funayama N, Gluck U, Gumbiner BM. Binding to cadherins antagonizes the signaling activity of beta-catenin during axis formation in Xenopus. J Cell Biol. 1996;132:1105–14.CrossRefPubMedGoogle Scholar
  11. Fang WQ, Ip JP, Li R, Ng YP, Lin SC, Chen Y, et al. Cdk5-mediated phosphorylation of Axin directs axon formation during cerebral cortex development. J Neurosci. 2011;31:13613–24. doi: 10.1523/JNEUROSCI.3120-11.2011.CrossRefPubMedGoogle Scholar
  12. Fei C, Li Z, Li C, Chen Y, Chen Z, He X, et al. Smurf1-mediated Lys29-linked Non-proteolytic Poly-ubiquitination of Axin Negatively Regulates Wnt/beta-catenin Signaling. Mol Cell Biol. 2013; doi: 10.1128/MCB.00418-13.PubMedCentralPubMedGoogle Scholar
  13. Fiedler M, Mendoza-Topaz C, Rutherford TJ, Mieszczanek J, Bienz M. Dishevelled interacts with the DIX domain polymerization interface of Axin to interfere with its function in down-regulating beta-catenin. Proc Natl Acad Sci USA. 2011;108:1937–42. doi: 10.1073/pnas.1017063108.PubMedCentralCrossRefPubMedGoogle Scholar
  14. Furuhashi M, Yagi K, Yamamoto H, Furukawa Y, Shimada S, Nakamura Y, et al. Axin facilitates Smad3 activation in the transforming growth factor beta signaling pathway. Mol Cell Biol. 2001;21:5132–41. doi: 10.1128/MCB.21.15.5132-5141.2001.PubMedCentralCrossRefPubMedGoogle Scholar
  15. Gao ZH, Seeling JM, Hill V, Yochum A, Virshup DM. Casein kinase I phosphorylates and destabilizes the beta-catenin degradation complex. Proc Natl Acad Sci USA. 2002;99:1182–7. doi: 10.1073/pnas.032468199.PubMedCentralCrossRefPubMedGoogle Scholar
  16. Gluecksohn-Schoenheimer S. The effects of a lethal mutation responsible for duplications and twinning in mouse embryos. J Exp Zool. 1949;110:47–76.CrossRefPubMedGoogle Scholar
  17. Guo X, Ramirez A, Waddell DS, Li Z, Liu X, Wang XF. Axin and GSK3- control Smad3 protein stability and modulate TGF- signaling. Genes Dev. 2008;22:106–20. doi: 10.1101/gad.1590908.PubMedCentralCrossRefPubMedGoogle Scholar
  18. Gwak J, Hwang SG, Park HS, Choi SR, Park SH, Kim H, et al. Small molecule-based disruption of the Axin/beta-catenin protein complex regulates mesenchymal stem cell differentiation. Cell Res. 2012;22:237–47. doi: 10.1038/cr.2011.127.CrossRefPubMedGoogle Scholar
  19. Hart MJ, de los Santos R, IN A, Rubinfeld B, Polakis P. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol. 1998;8:573–81.CrossRefPubMedGoogle Scholar
  20. Heasman J, Crawford A, Goldstone K, Garner-Hamrick P, Gumbiner B, McCrea P, et al. Overexpression of cadherins and underexpression of beta-catenin inhibit dorsal mesoderm induction in early Xenopus embryos. Cell. 1994;79:791–803.CrossRefPubMedGoogle Scholar
  21. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461:614–20. doi: 10.1038/nature08356.CrossRefPubMedGoogle Scholar
  22. Hughes TA, Brady HJ. Regulation of axin2 expression at the levels of transcription, translation and protein stability in lung and colon cancer. Cancer Lett. 2006;233:338–47. doi: 10.1016/j.canlet.2005.03.026.CrossRefPubMedGoogle Scholar
  23. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J. 1998;17:1371–84. doi: 10.1093/emboj/17.5.1371.PubMedCentralCrossRefPubMedGoogle Scholar
  24. Itoh K, Krupnik VE, Sokol SY. Axis determination in Xenopus involves biochemical interactions of axin, glycogen synthase kinase 3 and beta-catenin. Curr Biol. 1998;8:591–4.CrossRefPubMedGoogle Scholar
  25. Jacobs-Cohen RJ, Spiegelman M, Cookingham JC, Bennett D. Knobbly, a new dominant mutation in the mouse that affects embryonic ectoderm organization. Genet Res. 1984;43:43–50.CrossRefPubMedGoogle Scholar
  26. James RG, Davidson KC, Bosch KA, Biechele TL, Robin NC, Taylor RJ, et al. WIKI4, a novel inhibitor of tankyrase and Wnt/ss-catenin signaling. PLoS One. 2012;7:e50457. doi: 10.1371/journal.pone.0050457.PubMedCentralCrossRefPubMedGoogle Scholar
  27. Jho E, Lomvardas S, Costantini F. A GSK3beta phosphorylation site in axin modulates interaction with beta-catenin and Tcf-mediated gene expression. Biochem Biophys Res Commun. 1999;266:28–35. doi: 10.1006/bbrc.1999.1760.CrossRefPubMedGoogle Scholar
  28. Kanzaki H, Ouchida M, Hanafusa H, Yano M, Suzuki H, Aoe M, et al. Single nucleotide polymorphism of the AXIN2 gene is preferentially associated with human lung cancer risk in a Japanese population. Int J Mol Med. 2006;18:279–84.PubMedGoogle Scholar
  29. Kikuchi A. Roles of Axin in the Wnt signalling pathway. Cell Signal. 1999;11:777–88.CrossRefPubMedGoogle Scholar
  30. Kim MJ, Chia IV, Costantini F. SUMOylation target sites at the C terminus protect Axin from ubiquitination and confer protein stability. FASEB J. 2008;22:3785–94. doi: 10.1096/fj.08-113910.PubMedCentralCrossRefPubMedGoogle Scholar
  31. Kim S, Jho EH. The protein stability of Axin, a negative regulator of Wnt signaling, is regulated by Smad ubiquitination regulatory factor 2 (Smurf2). J Biol Chem. 2010;285:36420–6. doi: 10.1074/jbc.M110.137471.PubMedCentralCrossRefPubMedGoogle Scholar
  32. Kim SE, Huang H, Zhao M, Zhang X, Zhang A, Semonov MV, et al. Wnt stabilization of beta-catenin reveals principles for morphogen receptor-scaffold assemblies. Science. 2013;340:867–70. doi: 10.1126/science.1232389.PubMedCentralCrossRefPubMedGoogle Scholar
  33. Kim SI, Park CS, Lee MS, Kwon MS, Jho EH, Song WK. Cyclin-dependent kinase 2 regulates the interaction of Axin with beta-catenin. Biochem Biophys Res Commun. 2004;317:478–83. doi: 10.1016/j.bbrc.2004.03.065.CrossRefPubMedGoogle Scholar
  34. Kishida S, Yamamoto H, Ikeda S, Kishida M, Sakamoto I, Koyama S, et al. Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. J Biol Chem. 1998;273:10823–6.CrossRefPubMedGoogle Scholar
  35. Kusano S, Raab-Traub N. I-mfa domain proteins interact with Axin and affect its regulation of the Wnt and c-Jun N-terminal kinase signaling pathways. Mol Cell Biol. 2002;22:6393–405.PubMedCentralCrossRefPubMedGoogle Scholar
  36. Lammi L, Arte S, Somer M, Jarvinen H, Lahermo P, Thesleff I, et al. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet. 2004;74:1043–50. doi: 10.1086/386293.PubMedCentralCrossRefPubMedGoogle Scholar
  37. Lau T, Chan E, Callow M, Waaler J, Boggs J, Blake RA, et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res. 2013;73:3132–44. doi: 10.1158/0008-5472.CAN-12-4562.CrossRefPubMedGoogle Scholar
  38. Li L, Yuan H, Weaver CD, Mao J, Farr 3rd GH, Sussman DJ, et al. Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J. 1999;18:4233–40. doi: 10.1093/emboj/18.15.4233.PubMedCentralCrossRefPubMedGoogle Scholar
  39. Li Q, Lin S, Wang X, Lian G, Lu Z, Guo H, et al. Axin determines cell fate by controlling the p53 activation threshold after DNA damage. Nat Cell Biol. 2009;11:1128–34.CrossRefPubMedGoogle Scholar
  40. Li Q, He Y, Wei L, Wu X, Wu D, Lin S, et al. AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation. Oncogene. 2011;30:1194–204. doi: 10.1038/onc.2010.499.
  41. Li Q, Wang X, Wu X, Rui Y, Liu W, Wang J, et al. Daxx cooperates with the Axin/HIPK2/p53 complex to induce cell death. Cancer Res. 2007;67:66–74. doi: 10.1158/0008-5472.CAN-06-1671.CrossRefPubMedGoogle Scholar
  42. Liu W, Rui H, Wang J, Lin S, He Y, Chen M, et al. Axin is a scaffold protein in TGF-beta signaling that promotes degradation of Smad7 by Arkadia. EMBO J. 2006;25:1646–58. doi: 10.1038/sj.emboj.7601057.PubMedCentralCrossRefPubMedGoogle Scholar
  43. Lui TT, Lacroix C, Ahmed SM, Goldenberg SJ, Leach CA, Daulat AM, et al. The ubiquitin-specific protease USP34 regulates axin stability and Wnt/beta-catenin signaling. Mol Cell Biol. 2011;31:2053–65. doi: 10.1128/MCB.01094-10.PubMedCentralCrossRefPubMedGoogle Scholar
  44. Luo W, Ng WW, Jin LH, Ye Z, Han J, Lin SC. Axin utilizes distinct regions for competitive MEKK1 and MEKK4 binding and JNK activation. J Biol Chem. 2003;278:37451–8. doi: 10.1074/jbc.M305277200.CrossRefPubMedGoogle Scholar
  45. Luo W, Peterson A, Garcia BA, Coombs G, Kofahl B, Heinrich R, et al. Protein phosphatase 1 regulates assembly and function of the beta-catenin degradation complex. EMBO J. 2007;26:1511–21. doi: 10.1038/sj.emboj.7601607.PubMedCentralCrossRefPubMedGoogle Scholar
  46. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:9–26. doi: 10.1016/j.devcel.2009.06.016.PubMedCentralCrossRefPubMedGoogle Scholar
  47. Mai M, Qian C, Yokomizo A, Smith DI, Liu W. Cloning of the human homolog of conductin (AXIN2), a gene mapping to chromosome 17q23-q24. Genomics. 1999;55:341–4. doi: 10.1006/geno.1998.5650.CrossRefPubMedGoogle Scholar
  48. Mao J, Wang J, Liu B, Pan W, Farr 3rd GH, Flynn C, et al. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell. 2001;7:801–9.CrossRefPubMedGoogle Scholar
  49. Lyon MF, Rastan S, Brown SDM, editors. Genetic variants and strains of the laboratory mouse. Oxford: Oxford University Press; 1996.Google Scholar
  50. Miller JR, Moon RT. Signal transduction through beta-catenin and specification of cell fate during embryogenesis. Genes Dev. 1996;10:2527–39.CrossRefPubMedGoogle Scholar
  51. Miyaki M, Konishi M, Kikuchi-Yanoshita R, Enomoto M, Igari T, Tanaka K, et al. Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. Cancer Res. 1994;54:3011–20.PubMedGoogle Scholar
  52. Morrone S, Cheng Z, Moon RT, Cong F, Xu W. Crystal structure of a Tankyrase-Axin complex and its implications for Axin turnover and Tankyrase substrate recruitment. Proc Natl Acad Sci USA. 2012;109:1500–5. doi: 10.1073/pnas.1116618109.PubMedCentralCrossRefPubMedGoogle Scholar
  53. Najdi R, Holcombe RF, Waterman ML. Wnt signaling and colon carcinogenesis: beyond APC. J Carcinog. 2011;10:5. doi: 10.4103/1477-3163.78111.PubMedCentralCrossRefPubMedGoogle Scholar
  54. Nakamura T, Hamada F, Ishidate T, Anai K, Kawahara K, Toyoshima K, et al. Axin, an inhibitor of the Wnt signalling pathway, interacts with beta-catenin, GSK-3beta and APC and reduces the beta-catenin level. Genes Cells. 1998;3:395–403.CrossRefPubMedGoogle Scholar
  55. Noutsou M, Duarte AM, Anvarian Z, Didenko T, Minde DP, Kuper I, et al. Critical scaffolding regions of the tumor suppressor Axin1 are natively unfolded. J Mol Biol. 2011;405:773–86. doi: 10.1016/j.jmb.2010.11.013.CrossRefPubMedGoogle Scholar
  56. Ozaki S, Ikeda S, Ishizaki Y, Kurihara T, Tokumoto N, Iseki M, et al. Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer. Oncol Rep. 2005;14:1437–43.PubMedGoogle Scholar
  57. Parveen N, Hussain MU, Pandith AA, Mudassar S. Diversity of axin in signaling pathways and its relation to colorectal cancer. Med Oncol. 2011;28(Suppl 1):S259–67. doi: 10.1007/s12032-010-9722-x.CrossRefPubMedGoogle Scholar
  58. Perry 3rd WL, Vasicek TJ, Lee JJ, Rossi JM, Zeng L, Zhang T, et al. Phenotypic and molecular analysis of a transgenic insertional allele of the mouse Fused locus. Genetics. 1995;141:321–32.PubMedGoogle Scholar
  59. Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol 2012;4. doi: 10.1101/cshperspect.a008052.
  60. Rui HL, Fan E, Zhou HM, Xu Z, Zhang Y, Lin SC. SUMO-1 modification of the C-terminal KVEKVD of Axin is required for JNK activation but has no effect on Wnt signaling. J Biol Chem. 2002;277:42981–6. doi: 10.1074/jbc.M208099200.CrossRefPubMedGoogle Scholar
  61. Rui Y, Xu Z, Lin S, Li Q, Rui H, Luo W, et al. Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation. EMBO J. 2004;23:4583–94. doi: 10.1038/sj.emboj.7600475.PubMedCentralCrossRefPubMedGoogle Scholar
  62. Sakanaka C, Weiss JB, Williams LT. Bridging of beta-catenin and glycogen synthase kinase-3beta by axin and inhibition of beta-catenin-mediated transcription. Proc Natl Acad Sci U S A. 1998;95:3020–3.PubMedCentralCrossRefPubMedGoogle Scholar
  63. Schwarz-Romond T, Fiedler M, Shibata N, Butler PJ, Kikuchi A, Higuchi Y, et al. The DIX domain of Dishevelled confers Wnt signaling by dynamic polymerization. Nat Struct Mol Biol. 2007;14:484–92. doi: 10.1038/nsmb1247.CrossRefPubMedGoogle Scholar
  64. Shibata N, Tomimoto Y, Hanamura T, Yamamoto R, Ueda M, Ueda Y, et al. Crystallization and preliminary X-ray crystallographic studies of the axin DIX domain. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007;63:529–31. doi: 10.1107/S1744309107022579.PubMedCentralCrossRefPubMedGoogle Scholar
  65. Smalley MJ, Sara E, Paterson H, Naylor S, Cook D, Jayatilake H, et al. Interaction of axin and Dvl-2 proteins regulates Dvl-2-stimulated TCF-dependent transcription. EMBO J. 1999;18:2823–35. doi: 10.1093/emboj/18.10.2823.PubMedCentralCrossRefPubMedGoogle Scholar
  66. Song X, Wang S, Li L. New insights into the regulation of Axin function in canonical Wnt signaling pathway. Protein Cell. 2014;5:186–93. doi: 10.1007/s13238-014-0019-2.PubMedCentralCrossRefPubMedGoogle Scholar
  67. Spink KE, Polakis P, Weis WI. Structural basis of the Axin-adenomatous polyposis coli interaction. EMBO J. 2000;19:2270–9. doi: 10.1093/emboj/19.10.2270.PubMedCentralCrossRefPubMedGoogle Scholar
  68. Strovel ET, Wu D, Sussman DJ. Protein phosphatase 2Calpha dephosphorylates axin and activates LEF-1-dependent transcription. J Biol Chem. 2000;275:2399–403.CrossRefPubMedGoogle Scholar
  69. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene. 2002;21:4863–71. doi: 10.1038/sj.onc.1205591.CrossRefPubMedGoogle Scholar
  70. Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 2012;72:2822–32. doi: 10.1158/0008-5472.CAN-11-3336.CrossRefPubMedGoogle Scholar
  71. Wang S, Yin J, Chen D, Nie F, Song X, Fei C, et al. Small-molecule modulation of Wnt signaling via modulating the Axin-LRP5/6 interaction. Nat Chem Biol. 2013;9:579–85. doi: 10.1038/nchembio.1309.CrossRefPubMedGoogle Scholar
  72. Willert K, Shibamoto S, Nusse R. Wnt-induced dephosphorylation of axin releases beta-catenin from the axin complex. Genes Dev. 1999;13:1768–73.PubMedCentralCrossRefPubMedGoogle Scholar
  73. Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, Kikuchi A. Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability. J Biol Chem. 1999;274:10681–4.CrossRefPubMedGoogle Scholar
  74. Yamamoto H, Kishida S, Uochi T, Ikeda S, Koyama S, Asashima M, et al. Axil, a member of the Axin family, interacts with both glycogen synthase kinase 3beta and beta-catenin and inhibits axis formation of Xenopus embryos. Mol Cell Biol. 1998;18:2867–75.PubMedCentralCrossRefPubMedGoogle Scholar
  75. Yang LH, Xu HT, Li QC, Jiang GY, Zhang XP, Zhao HY, et al. Abnormal hypermethylation and clinicopathological significance of Axin gene in lung cancer. Tumour Biol. 2013;34:749–57. doi: 10.1007/s13277-012-0604-z.CrossRefPubMedGoogle Scholar
  76. Yardy GW, Bicknell DC, Wilding JL, Bartlett S, Liu Y, Winney B, et al. Mutations in the AXIN1 gene in advanced prostate cancer. Eur Urol. 2009;56:486–94. doi: 10.1016/j.eururo.2008.05.029.CrossRefPubMedGoogle Scholar
  77. Zeng L, Fagotto F, Zhang T, Hsu W, Vasicek TJ, Perry 3rd WL, et al. The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell. 1997;90:181–92.CrossRefPubMedGoogle Scholar
  78. Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R, et al. A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature. 2005;438:873–7. doi: 10.1038/nature04185.PubMedCentralCrossRefPubMedGoogle Scholar
  79. Zhang Y, Liu S, Mickanin C, Feng Y, Charlat O, Michaud GA, et al. RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. Nat Cell Biol. 2011;13:623–9. doi: 10.1038/ncb2222.CrossRefPubMedGoogle Scholar
  80. Zhang Y, Neo SY, Wang X, Han J, Lin SC. Axin forms a complex with MEKK1 and activates c-Jun NH(2)-terminal kinase/stress-activated protein kinase through domains distinct from Wnt signaling. J Biol Chem. 1999;274:35247–54.CrossRefPubMedGoogle Scholar
  81. Zhang YL, Guo H, Zhang CS, Lin SY, Yin Z, Peng Y, et al. AMP as a low-energy charge signal autonomously initiates assembly of AXIN-AMPK-LKB1 complex for AMPK activation. Cell Metab. 2013;18:546–55. doi: 10.1016/j.cmet.2013.09.005.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Institute of Biochemistry and Cell BiologyShanghai Institutes for Biological Sciences, Chinese Academy of SciencesShanghaiChina